318 related articles for article (PubMed ID: 9746765)
1. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening.
Williamson LM; Hackett G; Rennie J; Palmer CR; Maciver C; Hadfield R; Hughes D; Jobson S; Ouwehand WH
Blood; 1998 Oct; 92(7):2280-7. PubMed ID: 9746765
[TBL] [Abstract][Full Text] [Related]
2. Fetomaternal alloimmune thrombocytopenia.
Ahya R; Turner ML; Urbaniak SJ;
Transfus Apher Sci; 2001 Oct; 25(2):139-45. PubMed ID: 11761276
[TBL] [Abstract][Full Text] [Related]
3. Fetal and Neonatal Alloimmune Thrombocytopenia-New Prospects for Fetal Risk Assessment of HPA-1a-Negative Pregnant Women.
Kjeldsen-Kragh J; Bengtsson J
Transfus Med Rev; 2020 Oct; 34(4):270-276. PubMed ID: 33039264
[TBL] [Abstract][Full Text] [Related]
4. Alloimmunization to platelet antigen HPA-1a (PIA1) is strongly associated with both HLA-DRB3*0101 and HLA-DQB1*0201.
L'Abbé D; Tremblay L; Filion M; Busque L; Goldman M; Décary F; Chartrand P
Hum Immunol; 1992 Jun; 34(2):107-14. PubMed ID: 1358865
[TBL] [Abstract][Full Text] [Related]
5. HLA-DRB3*01:01 is a predictor of immunization against human platelet antigen-1a but not of the severity of fetal and neonatal alloimmune thrombocytopenia.
Wienzek-Lischka S; König IR; Papenkort EM; Hackstein H; Santoso S; Sachs UJ; Bein G
Transfusion; 2017 Mar; 57(3):533-540. PubMed ID: 28019029
[TBL] [Abstract][Full Text] [Related]
6. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a.
Turner ML; Bessos H; Fagge T; Harkness M; Rentoul F; Seymour J; Wilson D; Gray I; Ahya R; Cairns J; Urbaniak S
Transfusion; 2005 Dec; 45(12):1945-56. PubMed ID: 16371049
[TBL] [Abstract][Full Text] [Related]
7. Maternal DRB1*1501, DQA1*0102, DQB1*0602 haplotype in fetomaternal alloimmunization against human platelet alloantigen HPA-6b (GPIIIa-Gln489).
Westman P; Hashemi-Tavoularis S; Blanchette V; Kekomäki S; Laes M; Porcelijn L; Kekomäki R
Tissue Antigens; 1997 Aug; 50(2):113-8. PubMed ID: 9271820
[TBL] [Abstract][Full Text] [Related]
8. HLA-DRB3*01:01 exhibits a dose-dependent impact on HPA-1a antibody levels in HPA-1a-immunized women.
Kjeldsen-Kragh J; Titze TL; Lie BA; Vaage JT; Kjær M
Blood Adv; 2019 Apr; 3(7):945-951. PubMed ID: 30923048
[TBL] [Abstract][Full Text] [Related]
9. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn.
Killie MK; Husebekk A; Kjeldsen-Kragh J; Skogen B
Haematologica; 2008 Jun; 93(6):870-7. PubMed ID: 18443267
[TBL] [Abstract][Full Text] [Related]
10. Antenatal screening of unselected pregnant women for HPA-1a antigen, antibody and alloimmune thrombocytopenia.
Maslanka K; Guz K; Zupanska B
Vox Sang; 2003 Nov; 85(4):326-7. PubMed ID: 14633260
[No Abstract] [Full Text] [Related]
11. Antenatal screening for fetal alloimmune thrombocytopenia: the results of a pilot study.
Doughty HA; Murphy MF; Metcalfe P; Waters AH
Br J Haematol; 1995 Jun; 90(2):321-5. PubMed ID: 7794750
[TBL] [Abstract][Full Text] [Related]
12. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.
Ghevaert C; Campbell K; Walton J; Smith GA; Allen D; Williamson LM; Ouwehand WH; Ranasinghe E
Transfusion; 2007 May; 47(5):901-10. PubMed ID: 17465957
[TBL] [Abstract][Full Text] [Related]
13. Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome.
Kjeldsen-Kragh J; Fergusson DA; Kjaer M; Lieberman L; Greinacher A; Murphy MF; Bussel J; Bakchoul T; Corke S; Bertrand G; Oepkes D; Baker JM; Hume H; Massey E; Kaplan C; Arnold DM; Baidya S; Ryan G; Savoia HF; Landry D; Shehata N
Blood Adv; 2020 Jul; 4(14):3368-3377. PubMed ID: 32717028
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia.
Bertrand G; Martageix C; Jallu V; Vitry F; Kaplan C
J Thromb Haemost; 2006 Mar; 4(3):628-37. PubMed ID: 16460445
[TBL] [Abstract][Full Text] [Related]
15. HPA-1a antibody potency and bioactivity do not predict severity of fetomaternal alloimmune thrombocytopenia.
Ghevaert C; Campbell K; Stafford P; Metcalfe P; Casbard A; Smith GA; Allen D; Ranasinghe E; Williamson LM; Ouwehand WH
Transfusion; 2007 Jul; 47(7):1296-305. PubMed ID: 17581167
[TBL] [Abstract][Full Text] [Related]
16. The alloimmune response to the human platelet antigen-1a is not related to maternal-fetal killer immunoglobulinlike receptor/HLA-Cw combinations.
Valentin N; Gagne K; Kerdudou N; Hallé L; Kaplan C; Killie MK; Skogen B; Muller JY; Bignon JD
Transfusion; 2007 Dec; 47(12):2322-9. PubMed ID: 17714418
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of human platelet antigen (HPA)-1a and HPA-5b alloimmunised pregnancies and the association between platelet HPA-5b antibodies and symptomatic fetal neonatal alloimmune thrombocytopenia.
de Vos TW; Porcelijn L; Hofstede-van Egmond S; Pajkrt E; Oepkes D; Lopriore E; van der Schoot CE; Winkelhorst D; de Haas M
Br J Haematol; 2021 Nov; 195(4):595-603. PubMed ID: 34402048
[TBL] [Abstract][Full Text] [Related]
18. The prevalence of HPA-1a alloimmunization and the potential risk of FNAIT depend on both the DRB3*01:01 allele and associated DR-DQ haplotypes.
Ahlen MT; Heide G; Husebekk A; Skogen B; Kjeldsen-Kragh J; Stuge TB
Scand J Immunol; 2020 Jul; 92(1):e12890. PubMed ID: 32299122
[TBL] [Abstract][Full Text] [Related]
19. Foetal and neonatal alloimmune thrombocytopenia - The role of the HLA-DRB3*01:01 allele for HPA-1a-immunisation and foetal/neonatal outcome.
Kjeldsen-Kragh J; Ahlen MT
Transfus Apher Sci; 2020 Feb; 59(1):102707. PubMed ID: 31919011
[TBL] [Abstract][Full Text] [Related]
20. Severe neonatal alloimmune thrombocytopenia due to anti-HPA-3a.
Boehlen F; Kaplan C; de Moerloose P
Vox Sang; 1998; 74(3):201-4. PubMed ID: 9595650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
